CRISM Therapeutics Corporation (LON:CRTX – Get Free Report) insider Gerald Beaney acquired 20,182 shares of the stock in a transaction on Monday, April 7th. The shares were purchased at an average cost of GBX 988 ($12.62) per share, with a total value of £199,398.16 ($254,789.37).
CRISM Therapeutics Price Performance
LON:CRTX opened at GBX 8 ($0.10) on Thursday. CRISM Therapeutics Corporation has a 1-year low of GBX 5 ($0.06) and a 1-year high of GBX 30.90 ($0.39). The company has a market capitalization of £871,540.90, a PE ratio of -1.38 and a beta of 0.81. The firm’s 50-day moving average price is GBX 7.23 and its 200-day moving average price is GBX 8.73.
About CRISM Therapeutics
ChemoSeed, CRISM’s lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour.
Further Reading
- Five stocks we like better than CRISM Therapeutics
- EV Stocks and How to Profit from Them
- Quantum Computing: The $6.5 Billion Opportunity You Can’t Ignore
- How to Short Nasdaq: An Easy-to-Follow Guide
- Are Tariffs Threatening Disney’s Comeback Story?
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Is Alphabet a Generational Buying Opportunity at These Levels?
Receive News & Ratings for CRISM Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISM Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
